Treatment outcomes after highly active antiretroviral therapy: a meta-analysis of randomised controlled trials

Hogg, 1998, Improved survival among HIV-infected individuals following initiation of antiretroviral therapy, JAMA, 279, 450, 10.1001/jama.279.6.450 Palella FJ, 1998, Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators, N Engl J Med, 338, 853, 10.1056/NEJM199803263381301 Dybul, 2002, Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV, MMWR Recomm Rep, 51, 1 Thaker, 2003, HIV viral suppression in the era of antiretroviral therapy, Postgrad Med J, 79, 36, 10.1136/pmj.79.927.36 Kaufmann, 1999, Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy, Sex Transm Infect, 75, 218, 10.1136/sti.75.4.218 Egger, 2002, Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies, Lancet, 360, 119, 10.1016/S0140-6736(02)09411-4 1998, Report of the NIH Panel to Define Principles of Therapy of HIV Infection, MMWR Recomm Rep, 47, 1 2000, 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus, Clin Infect Dis, 30, S29 2003, Panel on Clinical Practices for Treatment of HIV Infection, Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, 1 Detels, 1998, Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators, JAMA, 280, 1497, 10.1001/jama.280.17.1497 Porter, 2003, Determinants of survival following HIV-1 seroconversion after the introduction of HAART, Lancet, 362, 1267, 10.1016/S0140-6736(03)14570-9 Mocroft, 2003, Decline in the AIDS and death rates in the EuroSIDA study: an observational study, Lancet, 362, 22, 10.1016/S0140-6736(03)13802-0 Robinson, 2002, Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed, Int J Epidemiol, 31, 150, 10.1093/ije/31.1.150 Derry, 2001, Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials, BMC Med Res Methodol, 1, 7, 10.1186/1471-2288-1-7 Ioannidis, 2001, Meta-analysis of randomised controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections, J Antimicrob Chemother, 48, 677, 10.1093/jac/48.5.677 O'Brien, 1996, Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS, N Engl J Med, 334, 426, 10.1056/NEJM199602153340703 Jordan, 2002, Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy, BMJ, 324, 757, 10.1136/bmj.324.7340.757 Schulz, 1995, Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials, JAMA, 273, 408, 10.1001/jama.1995.03520290060030 Jadad, 1996, Assessing the quality of reports of randomised clinical trials: is blinding necessary?, Control Clin Trials, 17(1), 1, 10.1016/0197-2456(95)00134-4 Ioannidis, 1998, Reporting of safety data from randomised trials, Lancet, 352, 1752, 10.1016/S0140-6736(05)79825-1 Ioannidis, 2001, Completeness of safety reporting in randomised trials: an evaluation of seven medical areas, JAMA, 285, 437, 10.1001/jama.285.4.437 Mantel, 1959, Statistical aspects of the analysis of data from retrospective studies of disease, J Natl Cancer Inst, 22, 719 DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 Lau, 1997, Quantitative synthesis in systematic reviews, Ann Intern Med, 127, 820, 10.7326/0003-4819-127-9-199711010-00008 Sterne, 2001, Meta-analysis in Stata, 357 Flandre, 2002, Adherence to antiretroviral therapy and outcomes in HIVinfected patients enrolled in an induction/maintenance randomised trial, Antivir Ther, 7, 113, 10.1177/135965350200700205 Flandre, 2002, Final analysis of the Trilege induciton-maintenance trial: results at 18 months, AIDS, 16, 561, 10.1097/00002030-200203080-00007 Rinaldo, 1999, Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens, J Infect Dis, 179, 329, 10.1086/314599 Pialoux, 1998, A randomised trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients, N Engl J Med, 339, 1269, 10.1056/NEJM199810293391802 Gulick, 1997, Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy, N Engl J Med, 337, 734, 10.1056/NEJM199709113371102 2000, Randomised, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients, AIDS, 14, 367, 10.1097/00002030-200003100-00009 Cameron, 1998, Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease, Lancet, 351, 543, 10.1016/S0140-6736(97)04161-5 Collier, 1996, Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group, N Engl J Med, 334, 1011, 10.1056/NEJM199604183341602 Garcia, 1999, A randomised study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study, AIDS, 13, 2377, 10.1097/00002030-199912030-00009 Garcia, 2000, Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages, J Acquir Immune Defic Syndr, 25, 26, 10.1097/00126334-200009010-00004 Gartland, 2001, AVANTI 3: a randomised, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients, Antivir Ther, 6, 127, 10.1177/135965350100600206 Goodgame, 2000, Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001, Antivir Ther, 5, 215, 10.1177/135965350000500306 Hammer, 1997, A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less, N Engl J Med, 337, 725, 10.1056/NEJM199709113371101 Haubrich, 1999, A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience, AIDS, 13, 2411, 10.1097/00002030-199912030-00013 Havlir, 1998, Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy, N Engl J Med, 339, 1261, 10.1056/NEJM199810293391801 Hirsch, 1999, A randomised, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy, J Infect Dis, 180, 659, 10.1086/314948 Opravil, 2000, Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomised trial of double versus triple therapy, J AIDS, 23, 17 Saag, 2001, Randomised, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients, AIDS, 15, 1971, 10.1097/00002030-200110190-00009 Stellbrink, 2000, Randomised, multicentre phase III study of saquinavir plus zidovudine plus zalcitabine in previously untreated or minimally pretreated HIVinfected patients, Clin Drug Invest, 20, 295, 10.2165/00044011-200020050-00001 1996 Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 Sterne, 2001, Investigating and dealing with publication and other biases in metaanalysis, BMJ, 323, 101, 10.1136/bmj.323.7304.101 Max, 2000, Management of the adverse effects of antiretroviral therapy and medication adherence, Clin Infect Dis, 30, S96, 10.1086/313859 Carr, 2000, Adverse effects of antiretroviral therapy, Lancet, 356, 1423, 10.1016/S0140-6736(00)02854-3 Moher, 2001, The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials, JAMA, 285, 1987, 10.1001/jama.285.15.1987 Moher, 1998, Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?, Lancet, 352, 609, 10.1016/S0140-6736(98)01085-X Ioannidis, 1997, The relationship between study design, results, and reporting of randomised clinical trials of HIV infection, Control Clin Trials, 18, 431, 10.1016/S0197-2456(97)00097-4 Pai, 2003, Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis, Lancet Infect Dis, 3, 633, 10.1016/S1473-3099(03)00772-2 Carr, 2002, Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy, Lancet, 360, 81, 10.1016/S0140-6736(02)09341-8 Loke, 2001, Reporting of adverse drug reactions in randomised controlled trials—a systematic survey, BMC Clin Pharmacol, 1, 3, 10.1186/1472-6904-1-3 Piantodosi, 2003, Larger lessons from the Women's Health Initiative, Epidemiology, 14, 6, 10.1097/00001648-200301000-00004 Ioannidis, 1997, The impact of high-risk patients on the results of clinical trials, J Clin Epidemiol, 50, 1089, 10.1016/S0895-4356(97)00149-2 Chesney, 1999, Adherence: a necessity for successful HIV combination therapy, AIDS, 13, S271 Haubrich, 1999, The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response, AIDS, 13, 1099, 10.1097/00002030-199906180-00014 Bassetti, 1999, Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study, J Acquir Immune Defic Syndr, 21, 114 Mehta, 1997, Potential factors affecting adherence with HIV therapy, AIDS, 11, 1665, 10.1097/00002030-199714000-00002 Ammassari, 2001, Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection, J Acquir Immune Defic Syndr, 28, 445, 10.1097/00042560-200112150-00006 Chesney, 2000, Factors affecting adherence to antiretroviral therapy, Clin Infect Dis, 30, S171, 10.1086/313849 Heath, 2002, Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy, J Acquir Immune Defic Syndr, 31, 211, 10.1097/00126334-200210010-00012 Aversa, 1996, Psychosocial aspects of antiretroviral medication use among HIV patients, Patient Educ Couns, 29, 207, 10.1016/0738-3991(96)00910-X